CA
NZ
UK
AU
IND
US
Zoetis (NYSE:ZTS) closed at $77.29, up $1.26, or 1.66%, on the session. That gain is noise against the trend. The shares are down 48.06% over theTrailing 12 Monthsand sit close to the floor of a 52-week range of $71.47 to $160.48, leaving a marketCapitalizationof …
Zimmer Biomet (NYSE:ZBH) closed at $93.93, down 1.08%, after a 2.25% fall the previous session, a two-day slide of roughly 3.3% into the week the company reports second-quarter results. The move is small in isolation, but it caps a year that has gone nowhere: …
At last closing, Waters (NYSE:WAT) completed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions business, a transaction announced in July 2025 at an implied value of roughly $17.5 billion. The structure was a Reverse Morris Trust: BD separated the unit into a vehicle …
West Pharmaceutical Services (NYSE:WST) reported second-quarter 2026 results before the market opened on 23 July, and they were the strongest set the company has produced since pandemic-era demand unwound. Net sales of $872.3 million rose 13.8% as reported and 12.7% organically. AdjustedDiluted Earnings per …
STERIS plc (NYSE:STE) closed at $228.40 on Friday, down 1.22%, a second consecutive session of give-back after a sharp mid-summer run. The shares had climbed from $211.46 on 15 July to $234.83 on 29 July, roughly 11%, including a 5.5% jump on 28 July, …
Stryker (NYSE:SYK) reported second-quarter 2026 net sales of $6.6bn on 30 July, up 9.4% as reported and 9.0% organically, with adjusted earnings of $3.69 a share against a consensus near $3.49. On the surface this was the quarter the market had been waiting for …
Therapeutics (Nasdaq:SMMT). Shares of the Miami-based biotech closed at $13.02, down 3.12% and within eighty cents of the 52-week low of $12.25. The weakness sits awkwardly against the calendar: the FDA has set a goal action date of for ivonescimab in EGFR-mutated, non-squamous non-small …
Companies (Nasdaq:COO). Cooper's fiscal second quarter, covering the three months and reported on 4 June, was two stories filed under one headline. Revenue reached $1.082 billion, up 8% reported and 5% organically, and non-GAAPDiluted Earnings per Shareof $1.21 rose 26% year over year on …
Thermo Fisher Scientific (NYSE:TMO) reported second-quarter 2026 revenue of $11.99 billion on 23 July, up 10% from a year earlier, and raised its full-year outlook. AdjustedEarningsof $6.03 a share cleared a consensus of roughly $5.71, and revenue beat an $11.7 billion estimate. Shares responded …
United Therapeutics (Nasdaq:UTHR) reports second-quarter results before the open, and the setup is unusually contradictory. First-quarter revenue of $781.5 million was down 2% from $794.4 million a year earlier,Net Incomefell 15% to $274.9 million, andDiluted Earnings per Sharedropped to $5.82 from $6.63. Those are …
Please wait processing your request...